In contrast to serum, LRRK2 mutations were only associated with moderately reduced soluble immune markers in CSF. Analysis of 129 samples revealed six reduced analytes in subject carrying LRRK2 mutations (n=63) compared with those non-carriers (n=66), irrespective of PD status (Figure 3E). The gene discussed is LRRK2; the disease is Parkinson disease.